Tevogen Bio Holdings Files Q3 2024 10-Q

TL;DR

Tevogen Bio's Q3 10-Q is in, check financials and stock details.

AI Summary

Tevogen Bio Holdings Inc. filed its 10-Q for the period ending September 30, 2024. The company, formerly Semper Paratus Acquisition Corp., is involved in biological products. Key financial data and share structures, including common stock and warrants, are detailed within the filing.

Why It Matters

This filing provides investors with an update on Tevogen Bio's financial health and operational status for the third quarter of 2024, crucial for understanding its current business trajectory.

Risk Assessment

Risk Level: medium — As a biological products company, Tevogen Bio Holdings Inc. likely faces inherent risks related to research, development, regulatory approvals, and market adoption of its products.

Key Numbers

• 0.0001 — Par Value Per Share (Common stock par value as of September 30, 2024.)
• 11.50 — Warrant Exercise Price (Per share exercise price for warrants as of September 30, 2024.)

Key Players & Entities

• Tevogen Bio Holdings Inc. (company) — Filer of the 10-Q
• Semper Paratus Acquisition Corp. (company) — Former name of Tevogen Bio Holdings Inc.
• 2024-09-30 (date) — End of the reporting period
• 2024-11-19 (date) — Filing date

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value per share TVGN The Nasdaq
• $11.50 — sable for one share of Common Stock for $11.50 per share TVGNW The Nasdaq Stock Ma

Filing Documents

• form10-q.htm (10-Q) — 1261KB
• ex31-1.htm (EX-31.1) — 14KB
• ex31-2.htm (EX-31.2) — 14KB
• ex32-1.htm (EX-32.1) — 5KB
• ex32-2.htm (EX-32.2) — 5KB
• form10-q_001.jpg (GRAPHIC) — 14KB
• 0001493152-24-046839.txt ( ) — 5712KB
• tvgn-20240930.xsd (EX-101.SCH) — 40KB
• tvgn-20240930_cal.xml (EX-101.CAL) — 53KB
• tvgn-20240930_def.xml (EX-101.DEF) — 246KB
• tvgn-20240930_lab.xml (EX-101.LAB) — 376KB
• tvgn-20240930_pre.xml (EX-101.PRE) — 324KB
• form10-q_htm.xml (XML) — 747KB

Signatures

Signatures 34 i PART I – FINANCIAL INFORMATION Item 1. Financial Statements (Unaudited) Tevogen Bio Holdings Inc. UNAUDITED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2024 2023 Assets Current assets: Cash $ 2,330,681 $ 1,052,397 Prepaid expenses and other assets 1,038,217 670,582 Due from related party 158,819 — Total current assets 3,527,717 1,722,979 Property and equipment, net 336,994 458,651 Right-of-use assets - operating leases 291,485 469,862 Deferred transaction costs — 2,582,870 Other assets 133,276 271,141 Total assets $ 4,289,472 $ 5,505,503 Liabilities and stockholders' deficit Current liabilities: Accounts payable $ 5,838,362 $ 3,418,378 Accrued expenses and other liabilities 1,405,403 1,096,450 Operating lease liabilities 258,507 252,714 Notes payable 1,651,000 — Convertible promissory notes — 80,712,000 Loan agreement 1,012,466 — Due to related party 250,000 — Total current liabilities 10,415,738 85,479,542 Convertible promissory notes — 14,220,000 Operating lease liabilities 42,567 234,858 Derivative warrant liabilities 14,572 — Written call option derivative liabilities 7,064 — Total liabilities 10,479,941 99,934,400 Stockholders' deficit Series A Preferred Stock, $ 0.0001 par value; 2,000 shares authorized; 500 shares issued and outstanding as of September 30, 2024 2,799,990 — Series C Preferred Stock, $ 0.0001 par value; 600 shares authorized; 400 shares issued and outstanding as of September 30, 2024 4,000,000 — Preferred Stock Value - — Common stock, $ 0.0001 par value; 800,000,000 shares authorized; 170,773,864 and 119,999,989 shares issued and outstanding at September 30, 2024 and December 31, 2023 17,078 12,000 Additional paid-in capital 90,933,028 5,216,840 Accumulated deficit ( 103,940,565 ) ( 99,657,737 ) Total stockholders' deficit ( 6,190,469 ) ( 94,428,897 ) Total liabilities and s

View Full Filing

View this 10-Q filing on SEC EDGAR